Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Tetrahydrofuran | HCID 8028 | — |
| Reactant | Morpholine | HCID 8083 | — |
| Reactant | 1-Ethyl-3-(3'-dimethylaminopropyl)carbodiimide | HCID 15908 | — |
| Reactant | 1-ethyl-3-methyl-5-(5-m-tolyl-2-trifluoromethyl-3H-imidazol-4-yl)-1,3-dihydro-benzoimidazol-2-one | HCID 22063922 | — |
| Catalyst | Dimethylformamide | HCID 6228 | — |
| Product | HCID 22063804 | HCID 22063804 | — |
Reaction Steps
A mixture of 1-ethyl-3-methyl-5-(5-m-tolyl-2-trifluoromethyl-3H-imidazol-4-yl)-1,3-dihydro-benzoimidazol-2-one (prepared as described above, 50 mg, 0.13 mmol), N,N-dimethylaminopyridine (48.7 mg, 0.40 mmol), EDCI (38.3 mg, 0.20 mmol) and morpholine (17.4 mg, 0.20 mmol) was stirred at room temperature in THF (1.33 mL) at room temperature. One drop of DMF was added to ensure solubility. The reaction mixture was allowed to stir overnight. The mixture was concentrated in vacuo, taken up in methylene chloride and washed with 10% aqueous citric acid. The organic phase was dried over anhydrous sodium sulfate and concentrated in vacuo to afford a reddish-brown solid, which was recrystallized in diisopropyl ether to give 19 mg of the title compound. MS (M+1)=446.5.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US07056918B2 |
|---|
| Source dataset | uspto-grants-2006_06 |
|---|
| ORD ID | ord-f33bed92781240afb07925a94bdfafe7 |
|---|
| Source note | uspto-grants-2006_06 |
|---|